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Stereotactic ablative radiotherapy (SABR), or stereotactic body radiotherapy (RT), is now established as a guideline-specified curative treatment option for patients present-
ing with early stage non–small-cell lung cancer (NSCLC) that are unfit for surgical resec-
tion.1,2 Long-term follow-up in a series of 676 patients revealed local control was 90% at 
5-years, with regional and distant recurrences in 13% and 20% of patients, respectively.3 As 
SABR is delivered on an outpatient basis, typically in as few as three treatment sessions, it 
is well tolerated by the elderly and those with comorbidities. In addition, prospective stud-
ies have established that SABR does not adversely impact patient-reported quality of life.4
SABR was pioneered in the early 1990s by clinicians in Scandinavia and Japan,5 and 
was adopted soon after by some centers in Germany. In this issue, Guckenberger et al.6 
report patterns of care for 582 patients treated in 13 German and Austrian centers between 
1998 and 2011. With one exception, these were all academic centers. Pretreatment histo-
logic diagnosis was available in 85% of patients, and high-grade toxicity was uncommon. A 
rapid increase in the number of patients treated was observed in recent years, mirroring the 
situation in The Netherlands and United States.7,8 A range of dose-fractionation schemes 
were used, reflecting the evolving experience with SABR over time. Similarly, SABR deliv-
ery techniques evolved reflecting the availability of improving technology, and by 2011, 
92% of all treatments used daily in-room image guidance immediately before treatment to 
ensure accuracy.
In keeping with a previous report,9 Guckenberger et al.3 found that delivery of bio-
logically effective doses of at least 106 Gy were associated with local control rates in excess 
of 90%. Treatment outcomes were not associated with an apparent learning curve, and the 
authors observed that availability of improved treatment planning and image-guided SABR 
delivery paralleled the use of more effective doses. Their findings suggest that existing 
technical variations in SABR delivery could be of limited clinical significance, as long 
as effective planning target volume-encompassing threshold doses can be delivered in an 
accurate manner. The findings of the present study in 13 German and Austrian centers 
offers hope that reported SABR outcomes could be extrapolated to many of the 300 RT 
centers in these countries.10 The ability to reproduce SABR outcomes outside leading aca-
demic centers is supported by the finding of improved population-based survival in elderly 
Dutch patients with stage I NSCLC, in the 6-year period after the introduction of SABR.7
The growing availability of SABR, with its reproducible local control rates and 
low toxicity, make it increasingly important to address the unmet therapeutic needs on 
a population level. In many countries, the elderly with mainly smoking-related comor-
bidities, are the fastest growing population of lung cancer patients. Because of histori-
cal reasons, nationwide cancer registries have only recently become well established in 
Germany, when the Federal Cancer Registry Act came into force in 1995.11 However, data 
from the Surveillance, Epidemiology and End Results-Medicare database illustrate the 
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impact of these demographic changes.12 Between 1998 and 
2007, a marked increase was seen in the number of elderly 
patients with lung cancer and three or more comorbidities. 
During the same period, access to video-assisted thoracic sur-
gery increased threefold to 32%, despite which the proportion 
of patients in Surveillance, Epidemiology and End Results-
Medicare database who did not undergo any local treatment 
increased from 14.5% in 1998, to 18.5% in 2007. As access 
to SABR was relatively limited in the United States in 2007,8 
data from the Dutch cancer registry are encouraging. In The 
Netherlands, an absolute reduction of 7% in the untreated 
elderly patient population was observed in the 6 years after 
the introduction of SABR, which in turn resulted in a popu-
lation-based improvement in median survival of 9.3 months.7 
These findings suggest that SABR will become increasingly 
important to address the unmet therapeutic needs of the aging 
global population.
The rapid improvements in technology for SABR 
have led to greater clinician confidence in delivering cura-
tive doses. With SABR now poised to have a major impact 
on the treatment of early-stage NSCLC, programs to ensure 
compliance with current guidelines13,14 and to monitor out-
comes in populations are important. The need for continued 
audit is supported by analysis of quality-assurance data from 
prospective trials, which revealed that a failure to adhere 
to protocol-specified RT requirements was associated with 
decreased survival, poorer local control, and potentially 
increased toxicity.15
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